Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.65 |
| ▸ | CACNB1 | Q02641 | 7/20 | 0.65 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.65 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437724 | 1.00 | CACNA2D1 (0.65) | CACNA2D1CACNB1CACNA1CCACNA1ATDP1 | |
| SCHEMBL5742876 | 0.91 | CACNA1A (0.62) | CACNA2D1CACNB1CACNA1CCACNA1ATDP1 | |
| SCHEMBL5742878 | 0.91 | CACNA1A (0.62) | CACNA2D1CACNB1CACNA1CCACNA1ATDP1 | |
| SCHEMBL4187829 | 0.80 | CACNA2D1 (0.97) | CACNA2D1CACNB1CACNA1CCACNA1ACACNA1B | |
| SCHEMBL9501764 | 0.79 | ACE (0.55) | — | |
| SCHEMBL6435743 | 0.75 | DPP4 (0.58) | AGTR2 | |
| SCHEMBL6435738 | 0.75 | DPP4 (0.58) | AGTR2 | |
| SCHEMBL10333499 | 0.75 | TDP1 (0.50) | CACNA2D1CACNB1CACNA1CCACNA1ATDP1 | |
| SCHEMBL10334052 | 0.74 | CACNA1A (0.48) | CACNA2D1CACNB1CACNA1CCACNA1ATDP1 | |
| SCHEMBL26330969 | 0.74 | CACNA2D1 (0.81) | CACNA2D1CACNB1CACNA1CCACNA1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | CACNA2D1 1951/4885CACNB1 1439/4885CACNA1C 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.